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INTRODUCTION: Currently, final diagnosis of prostate cancer (PCa) is based on histopathological analysis of needle biopsies, but this
process often bears uncertainties due to small sample size, tumour focality and pathologist’s subjective assessment.
METHODS: Prostate cancer diagnostic signatures were generated by applying linear discriminant analysis to microarray and real-time
RT–PCR (qRT–PCR) data from normal and tumoural prostate tissue samples. Additionally, after removal of biopsy tissues, material
washed off from transrectal biopsy needles was used for molecular profiling and discriminant analysis.
RESULTS: Linear discriminant analysis applied to microarray data for a set of 318 genes differentially expressed between non-tumoural
and tumoural prostate samples produced 26 gene signatures, which classified the 84 samples used with 100% accuracy. To identify
signatures potentially useful for the diagnosis of prostate biopsies, surplus material washed off from routine biopsy needles from 53
patients was used to generate qRT–PCR data for a subset of 11 genes. This analysis identified a six-gene signature that correctly
assigned the biopsies as benign or tumoural in 92.6% of the cases, with 88.8% sensitivity and 96.1% specificity.
CONCLUSION: Surplus material from prostate needle biopsies can be used for minimal-size gene signature analysis for sensitive and
accurate discrimination between non-tumoural and tumoural prostates, without interference with current diagnostic procedures. This
approach could be a useful adjunct to current procedures in PCa diagnosis.
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Early diagnosis of prostate cancer (PCa), the second most common
cancer worldwide, is based on digital rectal examination and the
determination of prostate-specific antigen (PSA) blood levels,
followed by transrectal biopsy, an invasive procedure with
potential side effects, mainly infections and haemorrhage (Ferlay
et al, 2004). This combination of procedures is fraught with
diagnostic uncertainties, such thatB75% of biopsies prompted by
an elevated PSA are subsequently found not to bear detectable PCa
and around 15% of the patients with low PSA levels are
subsequently found to harbour a tumour (Thompson et al, 2004;
Schroder et al, 2009). In addition, the frequent focal involvement
and small volume of tumours can hamper a definitive diagnosis.
To increase diagnostic accuracy, an estimated 20% of biopsies are
submitted to immunohistochemical detection of basal-cell markers
and AMACR (a-methylacyl-CoA racemase). Still, up to 25% of
these biopsies remain without a definitive diagnosis due to
inconclusive results or tissue exhaustion (Browne et al, 2004;
Montironi et al, 2006) and are classified as atypical small acinar
proliferation (ASAP). Therefore, until more sensitive and specific
procedures are developed, it is mandatory to extract the maximum
information from such explorations.
The use of biological material that remains associated with
aspiration or biopsy needles has been explored in different organs
for morphological analysis, flow cytometry or molecular testing
(Perry and Johnston, 1985; Stomper et al, 1998, 2001; Akimaru
et al, 2004). In this study, we have explored the application of gene
signatures on material washed off from biopsy needles in the
diagnostic evaluation of prostate biopsies.
MATERIALS AND METHODS
Linear discriminant analysis
We previously identified a set of 318 genes whose expression levels
are highly discriminant between malignant and normal prostate
tissues (Bermudo et al, 2008). Microarray data sets from this study
are deposited in the array express repository under accession
number E-MEXP-1331. To the microarray data for the 27 samples
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of that study we added data for 57 unrelated samples, generated by
Liu et al (2006). The resulting data set for all 84 samples (19 non-
tumoural and 65 tumoural) was normalised with the robust
multiarray average method and then quantile normalised (Irizarry
et al, 2003, 2006). To identify minimal-size genesets capable of
optimally discriminating between malignant and normal samples,
we considered the expression values for the set of 318 genes in
these 84 samples. We performed linear discriminant analysis
(LDA) using three iterative approaches, two backward stepwise
(a deterministic mode and a stochastic mode) and one forward
stepwise. For the deterministic backward stepwise mode, we
removed from the 318 geneset at each step the 10% of genes with
the lowest contribution to the model and measured the classifica-
tion accuracy at each step by leave-one-out-cross validation
(LOOCV). For the stochastic backward stepwise mode, 50% of
the genes from the group of the 20% least significant genes were
randomly removed at each step, and the classification accuracy
tested by LOOCV. We ran five trials in this way. For the forward
stepwise LDA approach, data from all samples were used to
generate 10 training-set and test-set pairs by randomly selecting
75% of the samples to form the training set, the remaining samples
forming the test set. The best discriminant pair of genes from each
possible pairwise combinations was initially selected from the
training set as implemented in the MASS (Irizarry et al, 2006)
package of R (Venables and Ripley, 2002), tested by LOOCV and
used as a seed for increasing the number of genes, one at each
round, keeping those that performed best as assessed by LOOCV.
Genes with equal discriminating power were monitored and used
to build all possible alternative models. The performance of the
models generated in the training sets was measured by LOOCV,
and those yielding a 100% classification success were applied to
determine their classification accuracy on the corresponding test
sets. The Fisher’s linear discriminant function was calculated for
each generated model.
For LDA of transcriptional data for 11 genes differentially
expressed between non-tumoural and tumoural prostate tissues,
we used data obtained from the real-time RT–PCR (qRT–PCR)
analysis of samples washed off from prostate biopsy needles (see
Materials and Methods). An LDA iterative forward stepwise mode
was applied as described before to mean DCt data for these 11
genes in 28 tumoural and 26 non-tumoural samples.
Processing of residual material recovered from simulated
prostate biopsy needles
Freshly procured specimens were sampled with biopsy needles,
which were inserted once in the peripheral zone of each lobe.
The resulting tissue cores were removed for histopathological
examination, the empty needle was washed in RNAlater (Ambion,
Austin, TX, USA) and the recovered material stored until further
processing. Thirty-seven samples thus obtained from 27 radical
prostatectomies with adenocarcinoma were used as tumoural
cases, in which the simulated biopsy cores contained tumoural
glands. Eleven samples from tumour-free prostates were used as
non-tumoural cases (Table 1). Total RNA was isolated using the
RNeasy Kit (Qiagen, Valencia, CA, USA) and transcripts quantified
by qRT–PCR (Table 2).
Processing of prostate and colon tissues
Prostate tissues were obtained from patients undergoing radical
prostatectomy for clinically localised prostate adenocarcinoma
(14 non-tumoural and 34 tumoural; Table 3). Four normal colon
mucosa samples were obtained from colectomy specimens from
patients with colorectal adenocarcinoma. Total RNA was isolated as
described before from tissue cryosections and used for qRT–PCR
(Table 2). All tissue samples were obtained from the Tumour Bank-
Biobank of the Hospital Clı´nic-IDIBAPS, Barcelona, and cleared for
research use after local review board evaluation in compliance with
current Spanish laws, including informed written consent.
Processing of material washed off from transrectal
prostate biopsy needles
Transrectal prostate biopsies were performed in patients with PSA
levels 44 ng ml1 with a 10-core scheme, using a single needle per
patient. After each puncture, the tissue cylinder was removed and
the empty needle was briefly washed in sterile saline solution in
individual containers. All five tissue cores from one lobe were
processed jointly for histopathology and given a single diagnosis.
Washed-off samples were obtained from 27 patients diagnosed
with adenocarcinoma in the biopsy cores and 26 patients with a
non-tumoural diagnosis (Table 4). The latter had at least one
Table 1 Clinical and histological characteristics of the patients whose samples were used for simulated prostate biopsies
Tumoural samples Normal samplesa
Number of samples 37 Number of samples 11
Number of patients 27 Number of patients 6
Mean age (years) 62.32 (49–72) Mean age (years) 68.5 (57–82)
Mean PSA (ngml1) 10.13 (3.09–55.8) Mean PSA (ngml1)b 4.93 (2–7.1)
Median PSA (ngml1) 8 Median PSA (ngml1)b 5.3
Mean ratio free PSA/total PSA (%)c 15.3 (3.4–51.4) Mean ratio free PSA/total PSA (%)b 23.47 (18.1–33.2)
Median ratio free PSA/total PSA (%)c 10 Median ratio free PSA/total PSA (%)b 21.3
Gleason score (number of patients)
5 3
6 3
7 17
8 2
9 2
TNM stage (number of patients)
T2 15
T3 12
% of carcinoma in the tissue cored 38.4(o10–90)
Abbreviation: PSA¼ prostate-specific antigen. aNormal samples were obtained from tumour-free prostates from nodular hyperplasias and radical cystoprostatectomies. bData
not available for two patients. cData not available for 10 patients. dMean content of tumoural glands relative to the whole tissue.
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Table 2 Genes used in real-time RT–PCR analyses and their corresponding TaqMan probes
Gene symbol Description Experimenta Assay IDb
ABCC4 ATP-binding cassette, subfamily C (CFTR/MRP), member 4 2, 3 Hs00195260_m1
AMACR a-Methylacyl-CoA racemase 1, 2, 3 Hs00204885_m1
EPCAM Epithelial cell adhesion molecule 1, 2, 3 Hs00158980_m1
HPN Hepsin (transmembrane protease, serine 1) 1, 2, 3 Hs00170096_m1
MYO6 Myosin VI 2, 3 Hs00192265_m1
CSTA Cystatin A (stefin A) 2, 3 Hs00193257_m1
DST Dystonin 2, 3 Hs00794953_m1
EPHA2 EPH receptor A2 2, 3 Hs00171656_m1
KRT5 Keratin 5 1, 2, 3 Hs00361185_m1
LAMB3 Laminin, b3 1, 2, 3 Hs00165078_m1
SNAI2 Snail homologue 2 (Drosophila) 2, 3 Hs00161904_m1
RN18S1 RNA, 18S ribosomal 1 1, 2, 3 4342379-18S/Hs99999901_s1
Abbreviation: RT–PCR¼ reverse transcriptase polymerase chain reaction. aExperiment in which each probe was used. 1: washed-off samples from simulated prostate biopsy
needles; 2: whole tissue samples from prostate and colon; 3: washed-off samples from transrectal prostate biopsy needles. bManufacturer’s probe ID.
Table 3 Clinical and histological characteristics of prostate whole tissue samples
Tumoural samples Normal samples
Number of patients 34 Number of patients 14
Mean age (years) 64.3 (50–74) Mean age (years) 67 (56–73)
Mean PSA (ngml1)a 7.16 (3.58–19) Mean PSA (ngml1)a 7.11 (4.6–10)
Median PSA (ngml1)a 6.8 Median PSA (ngml1)a 7.3
Mean ratio free PSA/total PSA (%)b 10.73 (6–23) Mean ratio free PSA/total PSA (%)c 10.9 (7–15)
Median ratio free PSA/total PSA (%)b 9.6 Median ratio free PSA/total PSA (%)c 10.5
Gleason score (number of patients)
5 6
6 3
7 21
8 1
9 3
TNM stage
T2 22
T3 12
Tumoural epithelium (%)d 60 Percentage of non-tumoural epithelium (%)e 43
Abbreviation: PSA¼ prostate-specific antigen. aData not available for one patient. bData not available for eight patients. cData not available for 14 patients. dMean content of
tumoural glands relative to the whole tissue. eMean content of non-tumoural glands relative to the whole tissue.
Table 4 Clinical and histological characteristics of the patients whose prostate biopsy needles were used for residual sample retrieval and analysis
Tumoural wash-off samples Normal wash-off samples
Number of patientsa 27 Number of patients 26
Mean age (years) 66 (52–84) Mean age (years) 67 (57–78)
Mean PSA (ngml1)b 648 (1.47–10,230) Mean PSA (ngml1)c 13.24 (2.11–79)
Median PSA (ngml1)b 8 Median PSA (ngml1)c 8.14
Mean ratio free PSA/total PSA (%)d 18.1 (6.9–34) Mean ratio free PSA/total PSA (%)e 16.6 (9–24.7)
Median ratio free PSA/total PSA (%)d 15.9 Median ratio free PSA/total PSA (%)e 17.8
Gleason score (number of patients)
6 10
7 12
8 0
9 3
10 2
Mean % of carcinoma in the tissue coref 53.8 (o5–90)
Abbreviation: PSA¼ prostate-specific antigen. aFor one patient, both lobes were analysed. bData not available for eight patients. dData not available for 15 patients. cData not
available for six patients. eData not available for 10 patients. fMean content of tumoural glands relative to the whole tissue.
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additional benign prostate biopsy diagnosis, either previous or
subsequent to the biopsy used in this study. For each patient,
qRT– PCR analysis was performed on material washed off from
one lobe, selecting for tumoural samples the lobe with the highest
content of tumour, and for non-tumoural samples the lobe with
representative benign histology. Washed-off samples were cen-
trifuged, the pellet resuspended in RNA lysis buffer (Qiagen) and
stored at 80 1C until use. Samples washed off from each needle
puncture were processed separately to isolate total RNA followed
by qRT–PCR (Table 2).
Real-time RT–PCR
Total RNA was reverse-transcribed and cDNAs used for qRT–PCR
on custom-designed TaqMan Low Density Arrays (Applied
Biosystems, Foster City, CA, USA) in an ABI PRISM 7900HT
instrument. Table 2 summarises probe information. Data were
analysed using the SDS 2.3 software (Applied Biosystems). For
simulated biopsies, relative transcript quantification was deter-
mined by the DDCt method. For colonic and prostatic tissues, DCt
data were used to build hierarchical clusters by UPGMA
(unweighted pair group method with arithmetic mean) (Sneath
and Sokal, 1973). Pvclust was used to calculate probability values
for each cluster, using multiscale bootstrap resampling, with 10 000
simulations (Suzuki and Shimodaira, 2006). A cluster was
considered as stable when the AU (approximately unbiased)
P-values obtained were 495. For material washed off from
transrectal prostate biopsy needles, individual washed-off samples
with low input RNA (Ct (18S) 418.5) were discarded, cases with
less than three washed-off samples with available valid qRT–PCR
data were excluded from the analyses and mean DCt values of the
available washed-off samples for each case were used for LDA.
RESULTS
Generation of optimal gene signatures that discriminate
non-tumoural from tumoural prostate tissues
With the aim of identifying minimal-size gene signatures that
discriminate benign from tumoural prostate tissue, we applied
LDA, which identifies a group of variables (here, gene expression
levels) constituting a subset of a broader group, that can explain
the data differences observed between two classes of entities (here,
non-tumoural and tumoural samples). The linear function related
to this signature can be used to assign new samples to its
corresponding class. We have applied two backward stepwise and
one forward stepwise approaches. The first two begin by building
a model with all available genes and at each step remove a
percentage of those that contribute less to the prediction of group
membership, and the last builds up the model by testing all genes
at each step and keeping the one that produces the most accurate
classification for the next round.
For our LDA analyses, we considered as a starting point the 318
genes selected from a previous work (Bermudo et al, 2008) as those
with the most significant differential expression between benign
and adenocarcinoma prostate tissue samples. To the microarray
data for the original 27 samples of that study we added data for 57
unrelated samples, generated by Liu et al (2006), resulting in a
combined expression data set for a total of 84 samples, which
included 19 non-tumoural and 65 tumoural samples. Linear
discriminant analysis applied to the data for these 318 genes in
all 84 samples produced 26 distinct signatures, all of which
achieved 100% accuracy in classifying all 84 prostate samples as
either benign or tumoural. Figure 1 shows the performance of the
most interesting model obtained by each LDA approach, which
corresponds to the one containing the smallest numbers of genes.
With the deterministic backward stepwise approach, we obtained
17 models containing from 9 to 57 genes. Because this approach
was initiated with a relatively high number of genes, 318, the
contribution to sample classification of many genes in the first few
iterative rounds was quite low, which could cause the loss of useful
genes during the first rounds of iteration. Therefore, we have also
applied a second approach consisting in the removal of genes, at
each step, in a stochastic manner, from the group of less significant
genes. In the backward stochastic approach, we obtained three
models, containing from 18 to 23 genes. Supplementary Tables 1
and 2 show the genes contained in these models and the LDA
loadings calculated for each gene.
Using the forward stepwise LDA approach, we generated and
tested the models derived from all possible gene pairs indepen-
dently for each of the 10 training sets. We obtained 49 gene pairs,
ranked by their LOOCV classification accuracy, of which two pairs
were repeated in three different training sets and five pairs in two
training sets, while the remaining pairs were unique. The number
of times that each gene appears in any of the selected pairs is
summarised in Supplementary Table 3. Each of these pairs was
used as a seed for its corresponding training set, and one gene was
added at each step of the process. We collected the models
generated (n¼ 776) that achieved 100% classification accuracy as
confirmed by LOOCV, and tested them on their corresponding test
sets. We found that six models, each constituted by four genes, also
classified perfectly (100% accuracy) those samples in three of the
training-set/test-set groups (Supplementary Table 4).
These results show that different statistical approaches yield
many minimal-size genesets that allow excellent discrimination
between malignant and normal prostate tissues, based on their
gene expression profiles.
Classification of prostate biopsies as benign or tumoural
by transcriptional profiling of surplus material from
biopsy needles
Microarray hybridisation is not a first-choice technology in current
clinical practice because of sample size requirements and cost issues.
Practical diagnostic signatures would be those that can be used with
alternative techniques, such as qRT–PCR. Given the significant
differences in target sequences and intrinsic technological features, if
microarray data are used as a starting point for these molecular
diagnostic signatures, they must be first validated by qRT–PCR if
this technique is to be applied for diagnostic purposes.
Because our discriminant model building based on 318 genes
generated multiple optimal signatures, we next applied LDA by
departing from a reduced subset of 11 genes that had been
carefully validated by qRT– PCR (Bermudo et al, 2008), thus
offering a significant gain in confidence in their discriminant
capacity over genes not validated by this technique. Second,
because our aim was to generate gene signatures with clinical
applicability, while avoiding any interference with standard clinical
practice, we decided to perform transcriptional profiling solely on
the biological material that may remain attached to the biopsy
needle, which is normally discarded after biopsy, leaving the
biopsy cylinder entirely for routine diagnostic histopathological
assessment.
As a preliminary step to assess the feasibility of obtaining
meaningful transcriptional profiles from such material, we
simulated needle biopsies on prostates from radical prostatec-
tomies, processed the tissue cores for pathological evaluation and
washed the resulting empty biopsy needles to produce the material
(needle ‘wash-offs’) for transcriptomic analysis. We confirmed that
the amount and integrity of total RNA was adequate for qRT–PCR
analysis (RNA integrity number higher than 5), and used these
samples for qRT–PCR quantification of transcripts for five genes
well known as differentially expressed in PCa: AMACR (Luo
et al, 2002; Rubin et al, 2002), HPN (Dhanasekaran et al, 2001;
Luo et al, 2001; Magee et al, 2001) and EPCAM (Strnad et al, 1989;
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Poczatek et al, 1999), overexpressed in PCa, and LAMB3 (Hao
et al, 1996) and KRT5 (Ordonez, 1998; Abrahams et al, 2002),
underexpressed in PCa. Our results show that three of these genes
are also significantly differentially expressed in material washed off
from simulated biopsy needles (Figure 2A), demonstrating the
suitability of this material for sensitive transcript quantification.
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In transrectal prostate biopsies, the needle traverses rectal
tissues, is contaminated with peripheral blood and finally pierces
the prostate capsule before reaching the prostatic glands and
stroma. These tissues could potentially distort the profiles
generated for the scarce biological material contained in needle
washes and thus limit the discriminant power of gene signatures.
Therefore, we analysed the expression of the 11-gene set in non-
tumoural colorectal tissue, the major contaminant in actual
prostate biopsies. The resulting profiles were clearly different
(AU495) from those for benign or tumoural prostate tissues
(Figure 2B), suggesting that colorectal tissue that might attach to
biopsy needles should not introduce a significant bias on prostate-
specific transcriptional profiles.
We next assessed the applicability of gene signatures to residual
material from actual prostate needle biopsies, for which we
analysed material washed off from biopsy needles used on a total
of 53 patients (Table 4). Transcript levels for the 11 genes were
quantified by qRT–PCR and the resulting data used for LDA
model building, in which the expression profiles were bench-
marked against the histopathological diagnosis assigned to the
corresponding biopsy tissues. The best discriminant model
contained six genes (Table 5), four of which were overexpressed
(ABCC4, AMACR, HPN and MYO6) and two underexpressed
(CSTA and LAMB3) in PCa. By applying LDA with this gene
signature, 25 of 28 samples with a tumoural histological diagnosis
were assigned a tumoural molecular status, and 25 of 26 samples
that lacked tumoural glands by histological evaluation were
molecularly classified as non-neoplastic. Thus, our six-gene
signature applied to biopsy needle residual material showed a
92.6% concordance with the pathological diagnosis of the
corresponding biopsy cylinders, with a sensitivity of 88.8% and a
specificity of 96.1% (Figure 2C).
Interestingly, nine of the biopsies whose corresponding washed-
off samples were used required additional immunohistochemical
analyses to reach a definitive histopathological diagnosis of PCa
(six cases) or benign tissue (three cases). Eight out of these nine
samples (88.8%) were correctly classified as tumoural or non-
tumoural by the six-gene signature. These results suggest that
transcriptional profiling of residual material recovered from
prostate biopsy needles can achieve a diagnostic accuracy
(tumoural vs non-tumoural) comparable to the combination of
routine histological assessment and immunohistological analysis
of biopsy cylinders.
DISCUSSION
Two important challenges in PCa diagnosis are the limitations of
current serum markers for clinical screening and the limited
sensitivity of biopsy techniques, both with a significant proportion
of false or indeterminate results. The use of minimal genesets as
molecular classifiers for tumour diagnosis or subclassification is
therefore being actively explored in several neoplasms. We
approached this problem by applying LDA to a set of 318 genes,
which yielded multiple optimal signatures that discriminate non-
tumoural from tumoural prostate tissues. The high probability of
finding different discriminant solutions is rooted in the nature of
transcriptomics, which considers numerous variables, thus in-
creasing the likelihood of arriving at multiple discriminant models
(Ein-Dor et al, 2005; Grate, 2005; Dougherty and Brun, 2007;
Guillot et al, 2007). Many of these signatures contained non-
overlapping genes, which were not necessarily those most
differentially expressed between malignant and normal tissues.
This is because genes with similar expression profiles across
samples provide redundant information and are therefore
discarded in the model building process. This could partially
explain the divergences found between different studies describing
diagnostic and prognostic signatures.
The main objective of this study was to maximise the diagnostic
information obtained from prostate biopsies, for which we tested
the applicability of gene signatures on surplus material obtained
from biopsy needles that is normally discarded. The most
discriminant model generated for such samples contained six
genes, all previously associated with cancer, which confers our
signature an additional functional relevance (Tomlins et al, 2007;
Bermudo et al, 2008). This model showed 92.6% concordance
between the molecular profiling of needle washes and the
histopathological diagnosis of the corresponding biopsy cylinders.
Therefore, our results indicate that molecular profiling performed
on biological material that is routinely discarded, saline washes of
biopsy needles, can achieve a diagnosis of prostate malignancy
with an accuracy at least comparable to histopathological
assessment of biopsy tissues. The fact that three cases were
incorrectly classified as non-tumoural by molecular profiling
might be explained by an insufficient representation of tumoural
cells in that washed-off samples, given that the tissue from the
biopsy and the washed-off sample are expected to be complemen-
tary but different samples. Due to ethical constraints, we have not
performed molecular profiling on the biopsy cylinders. However,
given the high sensitivity and specificity of our molecular
diagnostic approach on residual material, it is reasonable to
assume that profiling of the biopsy tissues themselves should
afford even higher levels of diagnostic accuracy.
The high diagnostic accuracy of our approach is further
highlighted by the fact that nine of the biopsies (16.6%) required
immunohistochemical analysis in order to reach histopathological
diagnosis, of which eight were initially diagnosed correctly by our
molecular profiling approach. Of these cases, the only case initially
classified as non-tumoural histologically but as tumoural by our
approach might be found histologically positive for prostate
adenocarcinoma in subsequent biopsies, which are not presently
available.
Our six-gene signature was robust, discriminating benign from
malignant samples independent of Gleason scores and tumour cell
representations, which ranged from o5% to 90% of the total
tissue. This suggests that it could be a useful adjunct for the
management of biopsies with uncertain diagnoses. In Europe,
there were 382 000 estimated new cases of PCa in 2008, implying
that 41.5 million biopsies were performed, of which B300 000
could not be diagnosed by morphological criteria alone and
required additional immunohistochemical assays (Ferlay et al,
2010). Importantly, even after immunohistochemical analysis,
470 000 cases were likely diagnosed as ASAP, which is associated
with a PCa risk of around 40% in subsequent explorations
(Montironi et al, 2006). Many of these diagnoses could potentially
have been avoided with the application of complementary methods
to enhance the sensitivity of routine biopsy diagnostic procedures.
We propose a hypothetical diagnostic course of action in which
material washed off from prostate biopsy needles could be initially
preserved, which implies a fast and economic way of collecting
samples that are normally discarded with the biopsy needle. Those
Table 5 Loadings of the six genes in the signature discriminant between
non-tumoural and tumoural wash-off samples from transrectal prostate
biopsies
Gene Loading Description
ABCC4 0.644969000296296 ATP-binding cassette, subfamily C
(CFTR/MRP), member 4
AMACR 0.336160831740741 a-Methylacyl-CoA racemase
CSTA 0.069085222 Cystatin A (stefin A)
HPN 0.852895826962963 Hepsin (transmembrane protease, serine 1)
LAMB3 0.0403965255185185 Laminin, b3
MYO6 0.266395575314815 Myosin VI
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cases with a negative or uncertain histopathological diagnosis
would be further processed for transcript quantification and
analysis of our six-gene signature. Cases with a ‘molecular-
negative’ result could resume a routine follow-up, whereas
‘molecular-positive’ cases would be advised immediate re-biopsy.
Our method can be implemented without introducing additional
surgical procedures or interfering with standard diagnostic
procedures. Given the high sensitivity of our model on extremely
scarce starting material, we further consider its possible use on
prostate biological material sampled with fine-needle aspiration,
whose smaller gauge would reduce side effects and patient
discomfort associated to needle biopsies.
In conclusion, surplus biological material from prostate needle
biopsies can be used for transcriptional profiling analysis to
provide a useful adjunct to current diagnostic procedures, without
causing any interference with the latter. Beyond the discriminant
power afforded by our six-gene model to detect prostate tumours,
our study highlights the many potential uses of a biological
material so far neglected but potentially important for PCa
management, including the accurate determination of multiple
prognostic or predictive molecular markers or signatures. Finally,
our approach could be also useful as an ancillary method in the
clinical management of other types of neoplasia.
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